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Patients with chronic obstructive pulmonary disease (COPD) often have difficulties with
keeping their weight. The aim of this investigation was to study nutritional status in
hospitalised Nordic COPD patients and to investigate the association between nutritional
status and long-term mortality in this patient group.
In a multicentre study conducted at four university hospitals (Reykjavik, Uppsala, Tampere
and Copenhagen) hospitalised patients with COPD were investigated. Patient height,
weight and lung function was recorded. Health status was assessed with St. George’s
Hospital Respiratory Questionnaire. After 2 years, mortality data was obtained from the
national registers in each country.
Of the 261 patients in the study 19% where underweight (BMI o20), 41% were of normal
weight (BMI 20–25), 26% were overweight (BMI 25–30) and 14% were obese. FEV1 was
lowest in the underweight and highest in the overweight group (p ¼ 0.001) whereas the
prevalence of diabetes and cardio-vascular co-morbidity went the opposite direction. Of
the 261 patients 49 (19%) had died within 2 years. The lowest mortality was found among
the overweight patients, whereas underweight was related to increased overall mortality.
The association between underweight in COPD-patients, and mortality remained
significant after adjusting for possible confounders such as FEV1 (hazard risk ratio (95%
CI) 2.6 (1.3–5.2)).Elsevier Ltd. All rights reserved.
6114077; fax: +46 18 6110228.
i.uu.se (R. Hallin).
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Nutritional status and long-term mortality in hospitalised patients with COPD 1955We conclude that COPD patients that are underweight at admission to hospital have a
higher risk of dying within the next 2 years. Further studies are needed in order to show
whether identifying and treating weight loss and depletion of fat-free mass (FFM) is a way
forward in improving the prognosis for hospitalised COPD patients.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is one of the
leading causes of disability and mortality in the world.1
COPD patients often have frequent exacerbation’s, and the
treatment of these exacerbation’s, are an important part of
the care of patients with COPD. Hospitalisations are
associated with further impairment of health status2 and
high cost.3 Studies on mortality after hospitalisation for an
acute exacerbation of COPD have shown a 1-year mortality
from 22 to 43%4,5 and a 2-year mortality of 29–49%,5–7 higher
mortality figures, from a study on hospitalised COPD
patients with oxygen treatment. High age, low FEV1,
reduced health status and co-morbidity are among the risk
factors that have been associated with increased mortal-
ity.4–7
Loss of body weight is a common and serious problem for
patients with COPD.8,9 Low body mass index (BMI) has been
found to be an independent predictor of morbidity10,11 and
mortality.10,12–15 Previous prospective studies in hospitalised
patients with COPD have, however, given diverging results
with some studies finding an independent relationship
between low BMI and mortality5,16 while other studies have
not found such an association.4,6 There are limited data on
BMI status and long-term mortality in COPD patients.
The aim of this investigation was to study nutritional
status in hospitalised Nordic COPD patients and to investi-
gate the association between nutritional status and long-
term mortality in this patient group.Materials and methods
Patients
This prospective study of patients hospitalised with acute
exacerbation’s of obstructive pulmonary disease in five
university hospitals in the Nordic countries has been
described previously.7,17,18 Consecutive patients that were
hospitalised due to a COPD exacerbation were included from
the participating hospitals. The study started in May 2000
and the last patient was included in June 2001. An acute
exacerbation was defined as a change in condition from
baseline, in a COPD patient, that was of such a magnitude
that the patient needed an acute hospital admission. All the
patients had COPD stage 1 or higher, according to the global
initiative for chronic obstructive lung disease (GOLD)
criteria.19 The investigators reviewed all records in order
to confirm diagnose. Only patients that were admitted for
more than 24 h were included.
In four of the five hospitals the protocol also included
measurement of body weight and length. The present
analysis includes 261 of the 316 patients (83%) fromReykjavik, Copenhagen, Uppsala and Tampere where height
was measured to the nearest 0.5 cm, while weight was
measured on a balance scale to the nearest 0.1 kg. BMI was
calculated as weight (kg)/length (m)2. Assessments were
made in the morning in a fasting state and within the first
48 h of admission.
A structured interview protocol was used and patients
were asked about smoking habits and social situation.
Health status (quality of life) was assessed using the
disease-specific St. George’s Respiratory Questionnaire
(SGRQ). This questionnaire has tree components: symptoms,
activity, impact and also a total score,20 higher scores
indicate worse health status. Psychological status was
assessed with the Hospital Anxiety and Depression Ques-
tionnaire (HAD), information on co-morbidity (diabetes and
cardiovascular disease) was obtained from patient records.
Spirometry was performed at discharge. Predicted values
for forced expiratory volume in 1 s (FEV1) were calculated
using reference values from the European Coal and Steel
Union.21
Two years after discharge information regarding death
and cause of death was obtained from the national registries
in each country. The immediate cause of death was divided
into the following categories. Respiratory causes (acute
COPD exacerbation’s (ICD 10 code J44.0 and J44.1),
respiratory insufficiency (J96) and pneumonia (J12-J18)):
cardio-vascular causes (myocardial infarction (I21), heart
failure (I50), stroke (I61 and I63) and rupture of aortic
aneurysms (I71)); malignancy (lung cancer (C34), leukaemia
(C91), lymphoma (C85) and abdominal tumour (D37)) and
others (septic shock (R57), aspiration (J69) and ileus (K56)).
IRB and/or ethic committee for each institution or
country approved the study and an informed consent was
obtained from all the patients.Statistics
Analysis was carried out using Stata 8.0 (Stata Corporation,
College Station, TX). Differences between patients in
different BMI-groups were performed by test of trends.
The test of trends was performed with linear regression for
continuous and logistic regression for nominal variables.
Simple and multiple linear regressions were used when
analysing the correlation between BMI and FEV1. The w
2-test
and the unpaired t-test were used when comparing patients
that had died during the study period. The time until death
was analysed by the Kaplan–Meier survival analysis and Cox
regression. The Cox regression model included all variables
that were found to be significantly related to mortality, in
the univariate analyses. Cox regression estimates (hazard
ratio) were also calculated by hospital and then combined,
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R. Hallin et al.1956using random effect meta-analysis. A p-value of o0.05 was
considered statistically significant.Results
Of the 261 patients (126 women and 135 men), 50 (19%)
were underweight (BMI o20), 107 (41%) where of normal
weight (BMI 20–25), 67 (26%) were overweight (BMI 25–30)
and 37 (14%) were obese (Table 1). FEV1 was lowest in the
underweight group and highest among the obese patients
while the prevalence of cardio-vascular disease and diabetes
went in the opposite direction. No significant differences
were found between the groups concerning smoking history,
health status or psychological status (Table 1). A significant
negative correlation was found between BMI and FEV1
(Table 1). This correlation remained significant after adjust-
ment for age, sex and pack years (po0.0001).
Of the 261 patients 49 (19%) had died within 2 years.
Baseline characteristics of surviving and non-surviving
patients are presented in Table 2. Patients that died during
the follow-up had a lower BMI, higher age, were more likely
to be men, had a lower FEV1, had more often diabetes and
had a lower health status than patients that survived.
The lowest mortality was found in overweight patients
(BMI 25–30 kg/m2) (Fig. 1). Also, after adjusting for otherTable 1 Baseline characteristics of the study patients, by BMI
BMI o20 (n ¼ 49) BMI 20–25 (n ¼ 108
Age 68712 71711
Women 43 56
FEV1% of predicted 29712 38719
Current smokers 33 25
Pack years 32721 41727
Living alone 55 56
Cardio-vascular 41 49
Diabetes 0 6
SGRQ total 55717 57717
HAD anxiety 874 7714
HAD depression 574 574
Table 2 Baseline characteristics of patients that survived or die
Survived (n ¼ 212)
BMI 25.175.3
Age 68712
Women 54
FEV1% of predicted 41719
Current smokers 25
Pack years 36725
Living alone 53
Cardio-vascular 43
Diabetes 9
SGRQ total 56717
HAD anxiety 774
HAD depression 573variables that were significantly related to mortality in the
univariate analyses (Table 3). Diabetes was the only other
risk factor that was significantly related to mortality in this
model.
Being underweight (BMI o20 kg/m2) was related to
increased overall mortality and respiratory mortality but
not to mortality of other causes (Fig. 2). There was no
significant difference between the centres in the association
between being under-weight and mortality (Fig. 3).Discussion
In this prospective study, we found that about one in five
of the patients hospitalised because of COPD was under-
weight (BMI o20 kg/m2). This group of patients was
almost three times more likely to die during the follow-up
period, than the patients with a higher BMI. The lowest
mortality was found in patients that were overweight
(BMI 25–30 kg/m2).
In our study poor nutritional status was clearly an
independent risk factor for higher mortality. This finding is
in accordance with studies on COPD patients treated with
long-term oxygen22,23 and is also in line with the results of
some5,16 but not all previous prospective studies of
hospitalised COPD patients.4,6 There were no significantcategories (mean7SD and %).
) BMI 25–30 (n ¼ 67) BMI 430 (n ¼ 27) Ptrend
6879 6778 0.16
48 35 0.33
40720 52718 o0.0001
25 22 0.28
35718 42725 0.34
52 51 0.60
49 73 0.009
13 24 o0.0001
56717 56717 0.83
674 774 0.30
574 574 0.79
d within the 2-year study period (mean7SD and %).
Died (n ¼ 49) P
22.775.6 0.0007
7279 0.0005
43 0.03
33714 0.0005
29 0.39
34720 0.59
51 0.74
50 0.18
16 0.03
63716 0.0002
7714 0.32
674 0.13
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Figure 1 Survival in relation to body mass index.
Table 3 Risk factors for mortality with in the 2-year study period.
Hazard risk ratio 95% CI P
BMI o20 kg/m2 12.9 2.8–59 0.001
BMI 20–25 kg/m2 6.5 1.5–28 0.01
BMI 25–30 kg/m2 1
BMI 430 kg/m2 7.7 1.5–40 0.02
Age per 10 years 1.3 0.92–1.9 0.13
Women 0.60 0.31–1.18 0.14
FEV1 per 10% of predicted 0.85 0.67–1.08 0.19
Diabetes 4.2 1.7–10 0.002
SGRQ total per 4 units 1.08 0.99–1.18 0.10
Adjusted for all the variables in the table and centre.
Figure 2 Risk of mortality in underweight patients (BMIo20 kg/m2) compared to patients with a BMI420 kg/m2 in relation to cause
of death (HRR ¼ hazard risk ratio). The HRR is adjusted for hospital, age, sex, FEV1, health status and diabetes.
Nutritional status and long-term mortality in hospitalised patients with COPD 1957differences in the association between BMI and mortality
between the different hospitals, which may be related to
similarities in the standards of COPD care within the Nordic
region.Risk factors for mortality in hospitalised COPD patients
were analysed in five Nordic hospitals.7 A drawback with our
previous report was that it did not include assessment of
nutritional status. In four of the five hospitals height and
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Figure 3 Adjusted hazard risk ratios and 95% confidence intervals of time to death in underweight patients (BMI o20 kg/m2)
compared to patients with a BMI420 kg/m2 (adjusted within hospital for age, sex, FEV1, health status and diabetes) with a combined
risk ratio (diamond indicates 95% confidence interval) from the model with centre as the random effect. The size of each square is
proportional to the sample size.
R. Hallin et al.1958weight was recorded in most of the patients and we
therefore decided to make a separate analysis on the
relationship between BMI and mortality based on data from
these four hospitals. As in our previous report we found that
diabetes was also independently associated with increased
mortality.7 In the present analysis the association between
mortality and FEV1 and health status was not statically
significant. The hazard risk ratios were, however, of the
same magnitude as in our previous analysis7 indicating that
the lack of significance was due to a smaller population
sample.
In the present study, patients with overweight had the
lowest overall mortality, this has also been found in other
COPD studies.12,13,24 Our results are also in accordance with
a Korean cohort study of the general population where a
decreasing risk of death by pulmonary causes with increasing
BMI was present.25 The reason for why, being overweight
may be a positive prognostic factor in COPD is to our
knowledge unknown.
The underweight patients had lower FEV1 but despite this
they had a similar level of smoke exposure in terms of pack
years as the patients that were normal or overweight. The
cause–effect relationship explaining the negative correla-
tion between FEV1 and BMI is unclear. The low BMI may be
caused by the more severe lung impairment, but it may also
reflect the findings of Harik-Khan et al.26, that low-weight
smokers are at a higher risk of developing COPD than normal
and overweight smokers. The underweight group had a
lower prevalence of co-morbidity, which may partly explain
why no difference was found in health status despite the
relatively large difference in FEV1.
The prognostic value of low BMI could be a result of COPD
terminal stage wasting. If this was the case, short time
mortality would be affected,27 but studies by Landbo et al.13
and Prescott et al.24 show that also long-term mortality washigher for patients with low BMI. Increased mortality in
underweight COPD patients probably have many causes,
some important suggestions are, direct effect on lung
function,28 loss of metabolically and functionally active
fat-free mass (FFM),29 decreased diaphragmatic muscle
strength.30 Underweight patients have increased exacerba-
tion frequency,10,31 and exacerbation’s lead to a faster
decline in FEV1,
32 impaired quality of life2 and also higher
mortality.5 This is consistent with our result that it is
pulmonary mortality and overall mortality that is increased.
Loss of body weight in COPD is of multifactorial origin.
Eating difficulties,33,34 higher metabolic rate and cost of
ventilation,35,36 together with oxidative stress causing
systemic inflammation27,37,38 are important factors. Cigar-
ette smoking causes oxidative stress by an imbalance
between oxidants and antioxidants, leading to systemic
inflammation,39,40 this inflammation persists even after
smoking sessation41 and is marked by increased levels of
CRP,42 fibrinogen27 and TNF-a.41 Patients with an increased
resting energy expenditure and decreased FFM, have been
found to have increased acute phase reactant proteins and
inflammatory cytokines and these findings may be causally
related.36 It has also been shown that starvation by itself
can cause emphysema-like changes in the lungs.28
When assessing nutritional status BMI is a measure that is
easy to use but it is a blunt tool. It is now getting more and
more common to use FFM as a measure of nutritional status
as it is getting easier to use bioelectrical impedance (BIA) in
larger studies. Recent data also show that FFM is a better
predictor of mortality and that FFM also predicts mortality
irrespective of fat mass.29,43
An important aspect of a poor nutritional status is that it
is potentially possible to treat. The importance of finding
and treating patients with weight loss and depletion of FFM
is stressed in COPD management recommendations.44
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Nutritional status and long-term mortality in hospitalised patients with COPD 1959Although Prescott et al.24 and Schols et al.12 have showed
that weight gain can reverse the increased mortality risk, it
has been difficult to show that that nutritional support alone
improves the prognosis in COPD.45 The reason might be the
above-discussed systemic inflammation and that in ad-
vanced stages of COPD, both energy balance and protein
balance is disturbed. Therefore, nutritional therapy may
only be effective if combined with exercise or other
anabolic stimuli.44
We conclude that COPD patients that are underweight at
admission to hospital for an exacerbation have a higher risk
of dying within the next 2 years and those COPD patients
with overweight have the significantly lowest mortality risk.
Further studies are needed in order to show whether
identifying and treating weight loss and depletion of FFM
is a way forward in improving the prognosis for hospitalised
COPD patients.Acknowledgements
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